Business
Repayment of Debt Facility
Repayment of Debt Facility.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 7435D Oxford Biomedica PLC 28 June 2019 \n\n \n \n \nOxford Biomedica \n \nRepayment of Debt Facility\n \n \nOxford, UK - 28 June 2019: Oxford Biomedica plc (LSE:OXB) (\"OXB\" or \"the Group\"), a leading gene and cell therapy group, announces that, further to the announcement of 28 May in relation to Novo Holdings' strategic investment in the Group and, in accordance with the stated use of proceeds from the transaction, Oxford Biomedica has now repaid in full its debt facility with Oaktree Capital Management. \n \n \n-Ends-\n \n\n\n\nEnquiries:\n\n\n \n\n\n\n\n \nOxford Biomedica plc\n \nJohn Dawson, Chief Executive Officer\nStuart Paynter, Chief Financial Officer\nCatherine Isted, Head of Corporate Development & IR\nSarah MacLeod, Head of Communications\n \n\n\n \n \n \nT: +44 (0)1865 783 000\nT: +44 (0)1865 783 000\nT: +44 (0)1865 954 161 / E: [email protected]\nT: +44 (0)7747 602 739 / E: [email protected]\n\n\n\n\n \nConsilium Strategic Communications\n \nMary-Jane Elliott/Matthew Neal\n\n\n \n \n \nT: +44 (0)20 3709 5700\n\n\n\n \n \n \nAbout Oxford Biomedica\n \nOxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the \"Group\") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com\n \n \n \n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approv...